Clinical trials: Refractory Plasma Cell Neoplasm
Multiple Myeloma
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard…
- Trial name
- NCT05016778
- Testing
- GPRC5D-CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang University
Multiple Myeloma
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
This is an open-label, multicenter clinical trial designed to evaluate the safety and potential efficacy of venetoclax and ABBV-838 combination therapy with dexamethasone in participants with relapsed or refractory multiple…
- Trial name
- NCT02951117
- Testing
- Venetoclax, ABBV-838, Dexamethasone
- Where
- 3 sites in Australia
- Sponsor
- AbbVie
AL Amyloidosis
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
The goal of this clinical trial is to evaluate the effectiveness and safety of CM-336, which is a BCMA/CD3 BiTE, in patients with relapsed/refractory AL amyloidosis or newly diagnosed AL amyloidosis with insufficient depth of…
- Trial name
- NCT06769555
- Testing
- CM-336 BCMA/CD3 bispecific antibody
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Relapsed/Refractory Multiple Myeloma, Multiple Myeloma
A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
This is a Phase 4, multicenter, open-label, single-arm study evaluating the safety and efficacy of elranatamab monotherapy in adult participants with relapsed or refractory multiple myeloma in India.
- Trial name
- NCT07881835
- Testing
- Elranatamab
- Volunteers
- 75 people
- Sponsor
- Pfizer
Relapsed/Refractory Multiple Myeloma
Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment
This study is a single-arm, single-center clinical study, with the main purpose of IIT clinical trials to evaluate the safety and initial efficacy of BCMA-GPRC5DCAR-T cells in subjects with relapsed/refractory multiple myeloma…
- Trial name
- r/r MM (NCT07195617)
- Testing
- BCMA-GPRC5D CART
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Multiple Myeloma
Study of Combination PS-341 and Thalidomide in Multiple Myeloma
The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate doses of PS-341 and thalidomide in the…
- Trial name
- NCT00083460
- Testing
- PS-341, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- University of Arkansas
Multiple Myeloma, Multiple Myeloma in Relapse
Universal CAR-T Cell Therapy for MM
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Trial name
- NCT07248176
- Testing
- Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Bioray Laboratories
Multiple Myeloma
Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide
This study will evaluate if the combination of Pomalidomide, Cyclophosphamide and Prednisone is safe and provides benefits in patients with multiple myeloma relapsed and/or refractory to lenalidomide.
- Trial name
- PCP (NCT01166113)
- Testing
- Pomalidomide, Cyclophosphamide, Prednisone
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Fondazione EMN Italy Onlus
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01678443
- Testing
- indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to find out whether inobrodib, when given with pomalidomide and dexamethasone, works better than standard treatment for people whose multiple myeloma has come back or has not improved after…
- Trial name
- DOMMINO-2 (NCT07772024)
- Testing
- InoPd, Investigator's choice of SAT
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- CellCentric Ltd.
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study.
- Trial name
- NCT06215118
- Testing
- Elranatamab, Iberdomide
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Vaccine Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response and kill their tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Trial name
- NCT00019097
- Testing
- autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Waldenström's Macroglobulinemia
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
This is a phase II study in relapsed/refractory WM patients treated with perifosine. It is designed to assess the proportion of overall confirmed responses (CR + PR + MR) using a two-stage phase II study design to permit early…
- Trial name
- NCT00398710
- Testing
- Perifosine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- AEterna Zentaris
Multiple Myeloma
Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors).
- Trial name
- NCT04650724
- Testing
- T cell infusion agent targeting BCMA chimeric antigen receptor
- Where
- China
- Volunteers
- 3 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Multiple Myeloma
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
The purpose of this study is to evaluate the effects of daratumumab monotherapy on bone disease in patients with relapsed/refractory MM who have received at least 2 prior lines of therapy, including lenalidomide and a PI.
- Trial name
- REBUILD (NCT03475628)
- Testing
- Daratumumab
- Where
- Greece
- Volunteers
- 57 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma and Plasma Cell Neoplasm
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-6 may stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with interleukin-6 may kill more cancer cells.
- Trial name
- NCT00470093
- Testing
- recombinant interferon-α, recombinant interleukin-6
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are few effective treatments for MM(multiple myeloma).
- Trial name
- NCT04637269
- Testing
- anti-BCMA CAR-T
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Xinqiao Hospital of Chongqing
Relapsed/Refractory Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination…
- Trial name
- NCT06655818
- Testing
- Belantamab Mafodotin, Dostarlimab
- Where
- 3 sites in France, South Korea
- Volunteers
- 4 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
- Trial name
- MM (NCT04960579)
- Testing
- P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
- Where
- 23 sites in United States
- Volunteers
- 275 people
- Sponsor
- Poseida Therapeutics, Inc.